Navigation Links
Ticagrelor: Considerable added benefit for specific patients
Date:10/11/2011

Since the start of 2011, the active ingredient ticagrelor can be prescribed in Germany in addition to acetylsalicylic acid (ASA) to avoid blood clots in patients with acute ischaemia of the cardiac muscle. The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined whether ticagrelor offers advantages to patients with acute coronary syndrome (ACS) in comparison with conventional drugs. This is the first co-called "early benefit assessment" that IQWiG has performed on the basis of a dossier provided by the manufacturer, in accordance with the new legal regulations.

The Institute has come to the conclusion that ticagrelor provides considerable added benefit to patients with "mild" myocardial infarction without the typical changes in the ECG (NSTEMI), as well as to patients with unstable angina pectoris, by reducing the risk of death and myocardial infarction. However, there is no corresponding proof for "severe" myocardial infarction (STEMI), in which there are usually characteristic changes in the ECG.

IQWiG assesses, G-BA decides

The company AstraZeneca developed the drug and introduced it to the German market at the start of 2011, under the trade name of Brillique. On 1 January 2011, the German Act on the Reform of the Market for Medicinal Products (AMNOG) came into force, which lays down that new pharmaceuticals should regularly be subjected to a benefit assessment. For this purpose, the pharmaceutical company must submit a dossier containing proof of the added benefit, in comparison to the "appropriate comparator". The latter is specified by the Federal Joint Committee (G-BA).

The G-BA is responsible for the overall process, but can commission IQWiG to assess the manufacturer's dossier - as happened with ticagrelor. IQWiG then issues a recommendation as to how the added benefit is to be classified. After the commenting procedure, the G-BA reaches a formal decision on this added benefit.
'/>"/>

Contact: Anna-Sabine Ernst
presse@iqwig.de
49-221-356-850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Considerable proportion of patients with advanced cancer continue to undergo common cancer screening
2. Hospitals encouraged to consider value-added service of hospital-based radiology groups
3. Pelvic Mesh for Incontinence May Carry Added Risk for Women: FDA
4. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
5. Newer Versions of the Pill Pose No Added Risk to Gallbladder
6. More Added Sugars, More Pounds?
7. Menthol Cigarettes Pose No Added Lung Cancer Risk: Study
8. Federal Supply Schedule pricing added to ProspectoRx from Elsevier/Gold Standard
9. Over 40 new titles added to Wiley-Blackwells journals program in 2011
10. Breastfeeding -- added protection for cancer survivors?
11. National Stroke Association survey reveals more than half of stroke survivors suffer added burden of little known neurologic condition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... CA (PRWEB) May 18, 2013 6Webs.com ... The simple to read reviews and comprehensive comparisons make ... impartial home security reviews. 6Webs.com just recently finished conducting ... system providers. , Tim Smythe from 6Webs.com reports, "There ... systems due to their ease of use, expandability and ...
(Date:5/18/2013)... Mexico, DF (PRWEB) May 18, 2013 ... by leading ayurvedic education institution in the West. Program ... Learning education. , Ayurveda is a healing modality practiced ... Ayurvedica ), it is considered that health begins when ... a profound understanding of their individual needs. Ayurveda aims ...
(Date:5/18/2013)... IL (PRWEB) May 18, 2013 The ... Oregon Gov. John A. Kitzhaber, M.D., (D) to sign ... law by prohibiting minors under the age of 18 ... would become the third state in the nation to ... have enacted similar indoor tanning bans for minors. Nationwide, ...
(Date:5/18/2013)... Ohio (PRWEB) May 18, 2013 ... Annual Conference, on May 17-22 in Austin, TX ... gather for educational and networking opportunities. , ... brushes, flexible scope repair capabilities and ... with valuable educational information on proper instrument care ...
(Date:5/18/2013)... John Ravera, D.D.S., a Newport Beach ... new member to his dental team, Courtney Marino. , Marino ... for over 10 years. She received her degree from West ... a member of Sigma Pi Alpha, a national honor society ... with patients of all ages, helping them understand the importance ...
Breaking Medicine News(10 mins):Health News:Best Wireless Home Security System Companies Released by 6Webs.com 2Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:ASDSA Urges Oregon Governor to Sign Under-18 Indoor Tanning Restrictions 2Health News:Spectrum Surgical Attends Society of Gastroenterology Nurses and Associates' (SGNA) 40th Annual Conference in Austin, TX 2Health News:Newport Beach Cosmetic Dentist John Ravera Adds New Member to Dental Team 2
... babies for the presence of a common infection was approved ... streptococcus// is a common infection that is passed from mother ... or even death. ,Although all women are tested ... leave some babies at risk for contracting an infection from ...
... certain premature babies to inhale small amounts of nitric ... bronchopulmonary dysplasia, according// to the results of two studies ... born with this condition each year in the United ... are too immature to mix inhaled air properly with ...
... considering becoming pregnant could prevent preeclampsia if they started ... following it up// during the first three months of ... blood pressure shoots up dangerously and could prove lethal ... of Pittsburgh say that this condition could be avoided ...
... the cornerstones of managing type 2 diabetes. But few ... ,Now, a new systematic review shows that exercise ... sensitivity to insulin, and decreases blood lipids (fats) while ... 2 diabetes is an increasing problem in Western societies ...
... of Medicine, University of California, Los Angels and Valencia, ... developed an alternative to the conventional epilepsy treatment. ... study and the clinical trails show that it has ... nerve that prevents seizures is stimulated to inhibit epilepsy. ...
... by Linda Chaudron, M.D., an assistant professor of psychiatry, pediatrics ... is a disorder which is fast rising among new mothers. ... screened for a period of 12 months after childbirth. Such ... as the symptoms, develop throughout the year. Only if ...
Cached Medicine News:Health News:FDA Approves New Test For Screening Infection In Babies 2Health News:FDA Approves New Test For Screening Infection In Babies 3Health News:Nitric Oxide Could Benefit Premature Babies 2Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 2Health News:Using Multivitamins Before And After Conception Averts Preeclampsia 3Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 2Health News:Exercise in Itself Improves Blood Glucose Control in Type 2 Diabetes 3Health News:Alternative to the Conventional Seizure Treatment 2Health News:Early Diagnosis of Postpartum Depression Is Very Essential Among New Mothers 2
(Date:5/17/2013)... , May 17, 2013  Boston Scientific Corporation (NYSE: ... the annual EuroPCR Scientific Program May 21-24 in ... to present a particularly rich and diversified set of ... Dawkins , M.D., global chief medical officer, Boston ... be presented, including the NG PROMUS trial, which evaluated ...
(Date:5/16/2013)...  PTC Therapeutics, Inc., today announced that it has ... U.S. Securities and Exchange Commission ("SEC") relating to the ... number of shares to be offered and the price ... (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ) J.P. ... managers for the offering. Cowen and Company is acting ...
(Date:5/16/2013)... and SYDNEY , May 16, 2013 /PRNewswire/ ... HIN), a leading innovator of less invasive, miniaturized circulatory support ... today announced that CEO Doug Godshall ... Conference at 11:00 a.m. EDT on Monday, May 20, 2013.  ... Sheraton New York Hotel. A live webcast of ...
Breaking Medicine Technology:Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2HeartWare Presentation At The 2013 UBS Global Healthcare Conference To Be Webcast 2
... biotechnology company,developing clinical stage treatments for cancer and ... from its Phase II,clinical trial of OncoVEX GM-CSF, ... at the 2008 Annual Meeting of the American,Society ... Clinical Trial Details, Phase II Trial Design: ...
... May 31 Millennium Pharmaceuticals, The Takeda,Oncology Company, ... trials of VELCADE based therapies that showed consistently ... diagnosed multiple,myeloma (MM). CR is one of the ... selected for oral presentation at the American Society,of ...
Cached Medicine Technology:BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 3BioVex Reports Positive Phase II Clinical Trial Results of OncoVEX GM-CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 2Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 3Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 4Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 5Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 6Multiple Clinical Trials of VELCADE(R) (Bortezomib) for Injection Based Therapies Demonstrate High Complete Remission Rates in Patients with Newly Diagnosed Multiple Myeloma 7
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (Z71,409-7) or contact custom...
... samples of moderate viscosity and density. Proven ergonomic design reduces hand fatigue, ... Volume Range (ul) ... 1.0~1.5 Imprecision(%) ... 10 ...
... is a fully adjustable, air-displacement pipette with ... the latest member of the Pipetman family, ... accuracy, and precision. We also added a ... our customers. Eight models cover the full ...
... Finnpipette Digital offers improved ergonomics for ... handle, modified grippy finger rest and ... comfort and efficiency. Finnpipette Digitals also ... gearing mechanism (pat. pend.) and super ...
Medicine Products: